Literature DB >> 16569781

Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience.

Chiao-Yun Chen1, Chun-Wei Li, Yu-Ting Kuo, Twei-Shiun Jaw, Ding-Kwo Wu, Jo-Chi Jao, Jui-Sheng Hsu, Gin-Chung Liu.   

Abstract

PURPOSE: To prospectively investigate the apparent diffusion coefficient (ADC) and choline levels measured at hydrogen 1 ((1)H) magnetic resonance (MR) spectroscopy, to monitor therapeutic responses of hepatocellular carcinoma (HCC) to transcatheter arterial chemoembolization (TACE).
MATERIALS AND METHODS: Institutional review board approval was obtained, and all patients and control subjects provided informed consent. Histologically proved large HCCs (>3 cm in diameter) were evaluated in 20 patients (16 men and four women; mean age, 59 years; range, 34-80 years) before TACE and 2-3 days after TACE. A control group of eight adults (five men and three women; mean age, 43 years; range, 24-76 years) with normal livers was examined by using the same protocol. Hepatic choline levels were measured by means of an external phantom replacement method, quantifying the peak at 3.2 ppm at (1)H MR spectroscopy. ADCs were measured for all lesions. A Wilcoxon rank sum test was used to compare absolute choline concentrations and ADCs at baseline between HCCs and normal liver parenchyma. Changes in choline levels and ADCs in the tumors before and after TACE were analyzed by using the Wilcoxon signed rank test.
RESULTS: The median preoperative choline level in patients with HCC (measured in 18 of the 20 patients) was 4.0 mmol/L (range, 0.0-17.2 mmol/L), which was significantly higher than that in patients with normal livers (n = 8) (median, 1.6 mmol/L; range, 0.0-2.1 mmol/L; P < .01). Among 18 patients with HCC, choline levels decreased significantly from before TACE to after TACE (P < .01). A significant increase in ADC from before TACE to after TACE in the 20 patients with HCC was also found (P < .01).
CONCLUSION: Hepatic choline levels and ADCs may allow monitoring of therapeutic responses of HCC to TACE although larger, more definitive and quantitative studies with clinical end points are needed. (c) RSNA, 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569781     DOI: 10.1148/radiol.2392042202

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  54 in total

1.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.

Authors:  Maïté Lewin; Laetitia Fartoux; Alexandre Vignaud; Lionel Arrivé; Yves Menu; Olivier Rosmorduc
Journal:  Eur Radiol       Date:  2010-08-05       Impact factor: 5.315

3.  Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization.

Authors:  Johnathan C Chung; Neel K Naik; Robert J Lewandowski; Jie Deng; Mary F Mulcahy; Laura M Kulik; Kent T Sato; Robert K Ryu; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

4.  The effect of gadoxetic acid enhancement on lesion detection and characterisation using T₂ weighted imaging and diffusion weighted imaging of the liver.

Authors:  S A Choi; S S Lee; I-H Jung; H A Kim; J H Byun; M-G Lee
Journal:  Br J Radiol       Date:  2010-12-01       Impact factor: 3.039

5.  Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.

Authors:  Sylvain Favelier; Louis Estivalet; Pierre Pottecher; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

Review 6.  Preoperative imaging for staging bladder cancer.

Authors:  Maxim J McKibben; Michael E Woods
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

Review 7.  Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Authors:  Z Yuan; W-T Li; X-D Ye; H-Y Zhu; W-J Peng
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

8.  Preliminary study of apparent diffusion coefficient assessment after ion beam therapy for hepatocellular carcinoma.

Authors:  Masayuki Kanamoto; Tosiaki Miyati; Kazuki Terashima; Daisaku Suga; Nobukazu Fuwa
Journal:  Radiol Phys Technol       Date:  2016-04-07

9.  C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients.

Authors:  Romaric Loffroy; Sylvain Favelier; Violaine Cherblanc; Louis Estivalet
Journal:  Quant Imaging Med Surg       Date:  2013-08

10.  3.0 T proton magnetic resonance spectroscopy of the liver: quantification of choline.

Authors:  Li Xu; Bo Liu; Yan Huang; Xian Liu; Si-Wei Zhang; Xue-Gang Xin; Jin-Zhi Zheng
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.